Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAL0921 in Glomerular Kidney Diseases and Proteinuria
NCT06466135Phase 2Recruiting
- Sponsor
- Walden Biosciences, Inc.
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and 2 more comparing WAL0921 with Placebo (2 arms). Primary endpoint: Incidence of treatment emergent adverse events at 36 weeks. Started Jul 2024; status: recruiting.
02
Drugs
WAL0921
03
Conditions
diabetic nephropathy (DN)focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)IgA nephropathy (IgAN)primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06466135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466135.